04:01 AM EDT, 10/12/2026 (MT Newswires) -- Valerio Therapeutics (ALVIO.PA) concluded the acquisition of healthcare technology company Etherna Immunotherapies, according to a Monday release. The biotechnology company acquired Etherna Immunotherapies for an enterprise value of 30 million euros, which was settled through cash and consideration shares. The acquisition is set to support Valerio Therapeutics' plan to develop its nucleic acid medicines portfolio.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.